As per the SNS Insider report titled, Pharmacogenomics Market Size, Share & Segmentation By Technology, Application, End User, Drug Type / Treatment Focus and Region | Global Forecast 2026–2035 “The global Pharmacogenomics Market was valued at USD 8.07 Billion in 2025 and is projected to reach USD 19.99 Billion by 2035, expanding at a CAGR of 9.50% during the forecast period of 2026-2035.”
This growth is mainly accelerated by the increasing adoption of precision medicine, rising volumes of genomic testing, increased development and use of companion diagnostics, and increased integration of AI-driven genomic analytics into the drug development and clinical decision-making landscape. According to industry analysis, increased investment directing towards genomic sequencing infrastructure and pharmacogenetic biomarker discovery is furthering growth opportunities related to commercialization prospects across oncology, cardiology, neurology, and rare disease therapeutics.
Pharmacogenomics as an industry is continually undergoing significant change as more and more healthcare systems adopt personalized approaches to medicine, which will enhance therapy effectiveness while reducing side effects. The U.S. FDA indicates that more than 450 drug labels have already been approved in terms of pharmacogenomic biomarkers. Moreover, with a rise in chronic illnesses and cancers, there is rising demand for genomic tests as a result of their ability to predict the patient’s response to treatment.
Growing Adoption of Precision Medicine and Companion Diagnostics Accelerates Global Market Expansion
A fast-growing number of precision medicine initiatives in healthcare systems of both developed and emerging nations is another factor promoting growth on the global pharmacogenomics market. National genome sequencing projects implemented by governments and health organizations aim at advancing disease prevention capabilities, increasing drug effectiveness, and saving costs of patients' hospitalization caused by their failure. As an example, more than one million people were involved in NIH All of Us Research program focused on advancing genomic science and personalized medicine.
Oncology continues serving as one of the principal markets promoting growth in adoption rates of pharmacogenomics solutions. It is mostly related to increasing usage of targeted therapies and companion diagnostics for cancer patients. Biomarkers-driven cancer therapy involving HER2 targeted breast cancer therapy and EGFR targeted lung cancer treatment have already shown considerable effectiveness. More and more pharmaceutical manufacturers incorporate pharmacogenomics analysis in their clinical trials in order to enhance the process of drug selection and reduce risks of failures in late stages of trials.
Advancements in next generation sequencing technology, PCR, microarray and artificial intelligence-based genomics solutions have increased reliability of genetic testing while reducing costs and decreasing turnaround time. Reduction of genome sequencing price makes this process available not only for research but also for clinical settings and hospitals in both developing and developed countries. Over the course of the last twenty years, the price of whole-genome sequencing fell by more than 99%.
Nevertheless, issues of genomic data security, insufficient insurance in emerging markets, high costs of implementation, lack of regulatory standards and inconsistencies in pharmacogenomic testing practices among various healthcare facilities are some of the factors restraining market development.
Key Report Highlights
- By technology, PCR dominated the Pharmacogenomics Market with approximately 35% revenue share in 2025, owing to its widespread clinical adoption, cost efficiency, and rapid turnaround capabilities. Meanwhile, Sequencing technologies are projected to register the fastest growth during 2026-2035 due to increasing utilization of next-generation sequencing platforms in precision oncology and rare disease diagnostics.
- By application, Oncology accounted for nearly 40% market share in 2025, driven by rising use of biomarker-based targeted therapies and companion diagnostics in cancer management. Cardiology is expected to emerge as the fastest-growing application segment due to growing pharmacogenomic testing adoption for anticoagulants and cardiovascular drug response optimization.
- By end user, Hospitals & Clinics held approximately 45% share in 2025, supported by increasing integration of genomic testing into routine clinical workflows. Pharmaceutical & Biotechnology Companies are anticipated to witness the fastest growth during the forecast period as drug developers increasingly utilize genomic data in clinical trials and precision drug development programs.
- By drug type/treatment focus, Targeted Therapy Drugs dominated with nearly 38% market share in 2025, owing to expanding utilization in oncology and rare genetic disorders. Immunotherapy Drugs are expected to record the fastest growth through 2035 due to increasing development of personalized immuno-oncology treatments and biomarker-driven immunotherapy selection strategies.
- Regionally, North America dominated the global Pharmacogenomics Market with approximately 40% market share in 2025, while Asia-Pacific is projected to register the fastest CAGR of 15.47% during 2026-2035.
Regional Outlook:
The dominant region of the Pharmacogenomics Market was North America in 2025, owing to its robust genomic testing facilities, high usage of precision medicines, favorable reimbursement policies, and substantial investments in biotech innovations. It includes key market participants and providers of genomic testing, along with advanced health systems that implement more clinical applications of pharmacogenetics testing guidelines. As per data from the Center for Disease Control and Prevention, over 1.3 million people visit hospital emergency departments annually because of adverse drug reactions, hence the need for individualized approaches to managing medicines.
As regards contribution to regional market revenues, the United States leads with growing uses of companion diagnostics and genomic sequencing in treating cancer and other rare diseases. There is increasing cooperation between big pharmas and genomic testing companies that can facilitate biomarker discovery in drug development projects. Besides, support from the FDA on companion diagnostics and pharmacogenomic labeling regulations will continue to boost market opportunities in clinical applications.
The Asia-Pacific region promises to be the fastest-growing market during the forecast period, expanding at a CAGR of 15.47%. Key drivers include healthcare spending, ongoing efforts in genomic research, cancer prevalence, and greater access to pharmacogenomic technologies in China, India, Japan, and South Korea. China makes massive investments into genomic medicine and AI-based healthcare services, whereas India is developing more genomic diagnostics thanks to partnerships between public and private healthcare companies in the field.
Europe offers promising market opportunities as well, owing to government-funded genomic projects and increasing use of personalized medicine approaches. Initiatives like the Genomics England project and EU precision healthcare investments will help develop regional capacity in genomic testing and related pharmacogenomics research.
Recent Industry Developments
- In March 2025, Illumina Inc. expanded its oncology-focused sequencing portfolio by introducing advanced multi-cancer genomic profiling solutions designed to improve precision treatment selection and biomarker detection efficiency.
- In January 2025, Thermo Fisher Scientific Inc. announced enhancements to its pharmacogenomics testing workflow solutions aimed at reducing turnaround times for clinical genomic analysis in hospital laboratories.
- In November 2024, QIAGEN N.V. strengthened its companion diagnostics capabilities through expanded partnerships with pharmaceutical developers focused on precision oncology therapeutics.
- In September 2024, Guardant Health, Inc. reported continued expansion of liquid biopsy applications for genomic-guided cancer treatment monitoring and therapy optimization.
- In 2025, several pharmaceutical companies accelerated integration of AI-driven pharmacogenomic analytics into drug development pipelines to improve patient stratification and clinical trial success rates.
Leading Companies in the Pharmacogenomics Market:
- Abbott Laboratories
- Agilent Technologies Inc.
- Becton, Dickinson and Company (BD)
- Bio-Rad Laboratories Inc.
- Centogene N.V.
- GeneDx (part of OPKO Health)
- Genomic Health, Inc. (Exact Sciences)
- Guardant Health, Inc.
- Hoffmann-La Roche Ltd.
- Horizon Discovery Group plc
- Illumina Inc.
- Invitae Corporation
- Myriad Genetics Inc.
- PathAI, Inc.
- PerkinElmer Inc.
- Personalis, Inc.
- QIAGEN N.V.
- SNPedia / OpenSNP
- Sophia Genetics
- Thermo Fisher Scientific Inc.
About the Author
Get in touch
